AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23076845
Drug: Oxandrolone 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.06 mg/kg per day
Trial: 14978854
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR = 2-3)
Trial: 1811815
Drug: Dalargin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalargin (1 mg bid)
Trial: 27225607
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2-propanol and benzalkonium chloride (group B)
Trial: 22509084
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg od
Trial: 22509084
Drug: Famotidine 10
RxNorm normalized name: famotidine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 10 mg bid plus mosapride 5 mg tid
Trial: 20132023
Drug: Zuspan's scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuspan's scheme (1 g/h by continuous intravenous infusion)
Trial: 20132023
Drug: Alternative scheme
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative scheme (2 g in bolus every two hours)
Trial: 18386570
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment for cancer (chemotherapy and radiotherapy)
Trial: 1960241
Drug: Plax pre-brushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plax pre-brushing rinse, 15 ml, rinsed twice daily for 30 seconds
Trial: 1960241
Drug: Placebo rinse,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rinse, 15 ml, rinsed twice daily for 30 seconds
Trial: 7346744
Drug: Indomethacin (IN)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (IN) 0.25 mg/kg orally for two doses, 24 hours apart
Trial: 29040812
Drug: Snacks made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snacks made from buckwheat (32 g serving; 141 kcal)
Trial: 29040812
Drug: Pita bread
RxNorm normalized name: Pita bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pita bread made from buckwheat flour (50 g serving; 135 kcal)
Trial: 19397753
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG) administered for 4 weeks
Trial: 19397753
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 4 weeks
Trial: 17977469
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (2, 4, or 6 g/d, 26% DHA, 6% EPA)
Trial: 8944401
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg IV cocaine hydrochloride
Trial: 2006595
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and Lidocaine
Trial: 6963328
Drug: moroxydine chloride
RxNorm normalized name: moroxydine
DrugBank: Moroxydine (DB13597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moroxydine chloride (0.04 g/kg a day)
Trial: 6963328
Drug: no specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no specific treatment (control)
Trial: 28485312
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of meropenem (loading dose of 0.5 g followed by 3 g/day)
Trial: 28485312
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of meropenem (initial dose of 1.5 g followed by 1 g every 8 hours)
Trial: 19531697
Drug: Perioperative β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative β-blocker use
Trial: 16855407
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori infection assessment using C‐urea breath test and anti‐H. pylori IgG antibody titers
Trial: 16855407
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of H. pylori infection
Trial: 12874393
Drug: 3,4-diaminopyridine (3,4-DAP)
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3,4-diaminopyridine (3,4-DAP) 20 mg
Trial: 8205303
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 mg/day)
Trial: 31228031
Drug: SHP465 mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP465 mixed amphetamine salts (MAS) 12.5-75 mg
Trial: 28728038
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation group treatment
Trial: 16234990
Drug: Intra-articular lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lavage with 5 l of saline
Trial: 16234990
Drug: Intra-articular lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lavage with 3 l of saline
Trial: 10993032
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens plus sequential norgestrel (CEEP) (n = 31)
Trial: 10993032
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment control (n = 50)
Trial: 7504880
Drug: Amiodarone 200
RxNorm normalized name: amiodarone 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 200 mg/day (n = 115)
Trial: 7504880
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 to 200 mg/day (n = 130)
Trial: 7504880
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic therapy (n = 123)
Trial: 3517508
Drug: Nifedipine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (200 micrograms/L)
Trial: 27307415
Drug: High-intensity atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity atorvastatin (80 mg/d before PCI and 40 mg/d thereafter for 1 year)
Trial: 27307415
Drug: Moderate-intensity atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity atorvastatin (20 mg/d for 1 year)
Trial: 24709487
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m², IV) + Vandetanib (100 mg daily, PO)
Trial: 24709487
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m², IV)
Trial: 22680916
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve analgesia (CFA), ropivacaine 25 mg bolus and 5 mg/h infusion for 24 hours after surgery.
Trial: 22680916
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics (control group).
Trial: 20228403
Drug: Valsartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (up to 160 mg daily)
Trial: 15953083
Drug: Control site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control site (left leg, no treatment)
Trial: 10578982
Drug: Antitubercular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitubercular treatment
Trial: 8340983
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg/d as calcium citrate malate)
Trial: 3729636
Drug: Usual oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oxygen prescriptions
Trial: 26742708
Drug: (131)I‐MIBG (444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I‐MIBG (444 or 666 MBq/kg) plus arsenic trioxide (0.15 or 0.25 mg/m(2))
Trial: 16415699
Drug: Sertraline (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (maximum dose of 200 mg/d)
Trial: 2639596
Drug: FIBS preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIBS preparation
Trial: 2639596
Drug: Typical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical treatment for uveitis
Trial: 9286518
Drug: 20% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sucrose solution dripped onto enamel blocks from 0 to 8 times/day
Trial: 3313776
Drug: Mesalazine (5-ASA)
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine (5-ASA) suppositories (3 x 250 mg/day)
Trial: 28811158
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral therapy (DAAs)
Trial: 18370982
Drug: Nebulized racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized racemic albuterol
Trial: 19573482
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 to 160 mg/day, administered b.i.d.
Trial: 16979126
Drug: Horse gram
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse gram lectin (Dolichos biflorus agglutinin) skin prick test (SPT) at 100 microg/mL
Trial: 15219008
Drug: Oropharyngeal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oropharyngeal vancomycin (0.5 g of a 4% gel at 6-hour intervals)
Trial: 9328328
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) treatment with IFN‐alpha2b (3 million units 3 times weekly for 12 months)
Trial: 4913623
Drug: Maximal doses
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal doses of histamine acid phosphate
Trial: 4913623
Drug: Supramaximal doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supramaximal doses of histamine acid phosphate
Trial: 4913623
Drug: Maximal doses
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal doses of pentagastrin
Trial: 4913623
Drug: Supramaximal doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supramaximal doses of pentagastrin
Trial: 31732851
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice (10 ml/kg/day)
Trial: 31732851
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (10 ml/kg/day)
Trial: 31234919
Drug: Tong‐luo Qu‐tong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tong‐luo Qu‐tong plaster administered externally for 14 days (two courses, once daily)
Trial: 31234919
Drug: Qi‐zheng Xiao‐tong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi‐zheng Xiao‐tong plaster administered externally for 14 days (two courses, once daily)
Trial: 28081543
Drug: Irinotecan/S‐1 (IRIS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan/S‐1 (IRIS) therapy
Trial: 23769807
Drug: N-acetylcysteine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine plus normal saline solution
Trial: 23769807
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution only
Trial: 23769807
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than 1 L intravenous fluids
Trial: 23769807
Drug: Greater than
RxNorm normalized name: immune globulin,alpha (IgA) greater than 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater than 1 L intravenous fluids
Trial: 19837206
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment (MT) + Cognitive Behavior Therapy (CBT)
Trial: 19837206
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment (MT)
Trial: 14699021
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg
Trial: 14699021
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) 0.3125 mg
Trial: 14699021
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg and 0.3125 mg
Trial: 9209015
Drug: Chemopreventive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemopreventive agents (specific agents not mentioned)
Trial: 8315422
Drug: Epirubicin 50
RxNorm normalized name: epiRUBicin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 50 mg/m2 on days 1 and 8 (every 3 weeks) with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group A)
Trial: 8315422
Drug: Epirubicin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin administered only on day 1 with fluorouracil (5 FU) and cyclophosphamide 500 mg/m2 on day 1 of each course (group B)
Trial: 29343468
Drug: Onabotulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Onabotulinum toxin-A (BoNT-A) injections (200 units: 60 into each masseter and 40 into each temporalis)
Trial: 24714351
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron
Trial: 24714351
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg elemental iron
Trial: 24714351
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg and 80 mg elemental iron
Trial: 19484401
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser irradiation treatment (diode laser)
Trial: 19484401
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride treatment (protective varnish)
Trial: 19001202
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens, 0.625 mg/d
Trial: 19001202
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus medroxyprogesterone acetate, 2.5 mg/d
Trial: 17033273
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg metoprolol tartrate
Trial: 8229609
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (OAC) therapy, 8.5 +/- 0.85 gms before meals
Trial: 2985395
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (single s.c. dose)
Trial: 26663540
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg Chromium picolinate (CrP) for 6 months
Trial: 20473540
Drug: Sham pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham pulsed electromagnetic field therapy (sham PEMF)
Trial: 18360659
Drug: Periodontal initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Periodontal initial therapy
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with high CD4 count (group 1A)
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine (40 micrograms per dose) in HIV/AIDS patients with low CD4 count (group 1B)
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine (20 micrograms per dose) in normal healthy controls (group II)
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine in all groups (HIV-positive and controls)
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine in patients with high CD4 count
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine in patients with low CD4 count
Trial: 16737046
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine in patients with CD4 count < 50
Trial: 1881582
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody OKT3
Trial: 6348424
Drug: 2 day
RxNorm normalized name: Sterapred 12 DAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin)
Trial: 6348424
Drug: 5 day
RxNorm normalized name: Fresh 5 Day Deodorant Pads
DrugBank: Aluminum chlorohydrate (DB11573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 day course of antibiotic prophylaxis (48 hours of intramuscular kanamycin and intravenous cephalothin followed by 3 days of oral cephalexin)
Trial: 26977602
Drug: Solution-focused CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused CBT (SFT)
Trial: 26977602
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PML and SFT)
Trial: 21917299
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (quinapril, losartan, amlodipine, hydrochlorothiazide, or bisoprolol) for 6 months
Trial: 12471004
Drug: Granisetron 20
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 20 micro g/kg
Trial: 12471004
Drug: Ramosetron 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 4 micro g/kg
Trial: 9796881
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (single dose)
Trial: 9796881
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg (once daily for 10 days)
Trial: 9796881
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (once daily for 10 days)
Trial: 9796881
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 10 days)
Trial: 7549418
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Vasoactive Intestinal Polypeptide (VIP)
Trial: 7549418
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Substance P (SP)
Trial: 2229528
Drug: Terbinafine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (125 mg taken twice daily)
Trial: 31344386
Drug: Topical coal
RxNorm normalized name: coal tar Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical coal tar treatment
Trial: 30251749
Drug: Ultrasound-guided interfascial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided interfascial injection (US-IFI)
Trial: 27150460
Drug: Lactoferrin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin and lactoperoxidase-containing tablets
Trial: 26187496
Drug: Lamotrigine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (up to 200mg per day, up to 400mg if taking combined oral contraceptives)
Trial: 19702677
Drug: UFH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH plus GP IIb/IIIa inhibitor
Trial: 17365760
Drug: Gabapentin 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 1,800 mg/day for 8 weeks
Trial: 15231010
Drug: Oral intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Trial: 15231010
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate (daily and intermittent)
Trial: 11234783
Drug: Patient-delivered partner
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-delivered partner medication (PDPM) for women